Structural & Drug Screening (SDS)

项目摘要/摘要(结构和药物筛选) 在之前的CCSG更新中，结构生物学(SB)和高通量筛选(HTS)都是 作为新的共享资源(SR)获得批准和资助。在项目期间，独立的SRS 为密歇根大学综合癌症中心(UMCCC)成员提供频繁协调的服务 提高癌症相关项目的效率和影响力。此次合作展示了 从项目启动开始就通力合作。SRS和UMCCC的领导人将SR的合并视为 这是一个自然发展的过程，是成员从这些重要资源中获得最大利益的一种方式。有了支持 来自UMCCC高级领导力的Janet Smith博士和联席主任Vince Groppi博士于2015年加入 他们正式将SRS合并为一个单位。在这个过程中，药物化学(MC)被添加到SR中 以满足癌症研究人员现有的需求。2016年，UMCCC批准成立了一个综合性的 统一设施、结构和药物筛选(SDS)SR。SDSSR使UMCCC成员能够使用 先进的基于结构的药物设计和/或无偏见的HTS策略，以确定可能是 通过里程碑驱动的研究计划推进，从而实现高效和有效的发现和 精准肿瘤学药物的发展；UMCCC的战略目标。这是通过使用三个 每一个服务学科都由一位经验丰富的教职员工领导指导：SB，在Dr。 史密斯；HTS，在格罗皮博士的指导下；MC，在安德鲁·怀特博士的指导下。服务请求中的 具有凝聚力的活动、服务和流程为UMCCC成员带来四个主要好处：i)项目是先进的 沿着转化管道，从基础科学发现到早期抗癌药物发现；ii)一个项目 管理人员指导研究人员有效和高效地使用与其需求相匹配的适当服务；三) 集成的团队方法为研究人员提供了完整的、一站式的专业知识集 研究人员可从精简的行政支助结构中节省费用。

PROJECT SUMMARY/ABSTRACT (STRUCTURE AND DRUG SCREENING) In the previous CCSG renewal, Structural Biology (SB) and High-Throughput Screening (HTS) were both approved and funded as new Shared Resources (SRs). During the project period, the independent SRs frequently coordinated services for University of Michigan Comprehensive Cancer Center (UMCCC) members to increase the efficiency and impact of cancer-related projects. This collaboration demonstrated the benefit of working together from project initiation. The SRs and UMCCC leaders viewed the amalgamation of the SR as a natural progression and a way for members to receive maximum benefit from these vital resources. With support from UMCCC Senior Leadership, Janet Smith, PhD was joined by Co-Director Vince Groppi, PhD in 2015 when they formally merged the SRs into one unit. During this process, Medicinal Chemistry (MC) was added to the SR to meet existing needs of cancer researchers. In 2016, UMCCC approved the establishment of a comprehensive unified facility, the Structure and Drug Screening (SDS) SR. The SDS SR enables UMCCC members to use advanced structure-based drug design and/or nonbiased HTS strategies to identify chemical matter that can be advanced through a milestone-driven research plan resulting in efficient and effective discovery and development of precision oncology medicines; a strategic goal of UMCCC. This is accomplished by use of three service disciplines, each of which is guided by an experienced faculty leader: SB, under the direction of Dr. Smith; HTS, under the direction of Dr. Groppi, and MC under the direction of Andrew White, PhD. The SR's cohesive activities, services and processes yield four key benefits to UMCCC members: I) projects are advanced along the translational pipeline, from basic science discoveries into early cancer drug discovery; II) a project manager guides researchers in the effective and efficient use of appropriate services matched to their needs; III) an integrated team approach provides researchers a complete, `one-stop' set of expertise for the duration of their projects; and IV) researchers accrue cost savings from a streamlined administrative support structure.